Goldman Sachs reiterated its Neutral rating on Allscripts Healthcare Solutions MDRX. At the same time, the rating agency left its price target on the company's stock unchanged at $21. On Tuesday, MDRX lost 7.05% of its value to end the day at $16.74. Its shares rebounded in today's pre-market trading, rising 1.67% to stand around $17.02.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
